Value Of Radiotherapy After Minimally Invasive Surgery In Patients With Stage IA1-IIA1 Cervical Cancer

Abstract

In this study, we aimed to estimate the value of adjuvant radiotherapy after receiving laparoscopic hysterectomy for stage IA1-IIA1 cervical cancer patients. Two hundred twenty-one women with cervical cancer of stage IA1-IIA1 were included in this retrospective analysis. Sixty-two of them were treated with laparoscopic hysterectomy and adjuvant radiotherapy (group A), 115 underwent open surgery (group B) and 44 performed laparoscopic hysterectomy alone (group C). The 3-year local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and overall survival (OS) rates were assessed in three groups. The median follow-up time was 58.33 months (range, 56.91–59.76 months) for all the patients. Three groups were comparable in terms of age, histologic subtypes, tumor size and ECOG Performance Status. The 3-year LRFS rates were 98.4% in group A, 97.4% in group B, 86.4% in group C, respectively. The LRFS rate of group A and B patients surpassed those of group C patients (group A vs. B, p = 0.634; group A vs. C, p = 0.011; group B vs. C, p = 0.006). The 3-year overall survival (OS) and 3-year DMFS rates were 96.8% and 93.5% in group A, 97.4% and 98.3% in group B, 93.2% and 97.7% in group C, respectively. The 3-year OS and DMFS rates were comparable in three groups (p>0.05). Adjuvant radiotherapy after laparoscopic hysterectomy in patients with early stage cervical cancer can reduce the risk of recurrence, and bring local control and survival benefits.